

## XI. News Releases

Major news releases during October 2012 - March 2013 are as below.

Please refer to our web site for details (<http://www.takeda.com/>).

Date	Summary
2-Oct-12	Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for the Treatment of Major Depressive Disorder
3-Oct-12	Takeda and Advinus Initiate Multi-year Drug Discovery Collaboration
5-Oct-12	Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
25-Oct-12	DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
30-Oct-12	Takeda Submits a New Drug Application for Cetilistat (Development Code: ATL-962) in Japan for the Treatment of Obesity with Complications
31-Oct-12	Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)
6-Nov-12	Takeda to Acquire Envoy Therapeutics, Inc.
10-Dec-12	Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study
11-Dec-12	Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting
18-Dec-12	Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical
25-Dec-12	Takeda Announces Mutual Termination of Amylin / Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
10-Jan-13	Lotriga® 2g Now Available for a Treatment of Hyperlipidemia in Japan
22-Jan-13	Takeda Establishes New Trading Company and Reinforces Business Structure in China
26-Jan-13	Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
28-Jan-13	Data From Post-Marketing Survey of Vectibix® for the Treatment of Colorectal Cancer Reported at American Society of Clinical Oncology, 2013 Gastrointestinal Cancers Symposium
13-Feb-13	Administrative Sanction Related to Voluntary Recall of ALINAMIN®-F5 Injection in Japan
21-Feb-13	Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
24-Feb-13	Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection
28-Feb-13	BENET® Tablets 75 mg, a Once-Monthly Formulation of an Antiosteoporotic Agent Now Available in Japan
28-Feb-13	Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8-Mar-13	Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
19-Mar-13	NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84
22-Mar-13	Takeda Submits New Drug Application for Brentuximab Vedotin in Japan
25-Mar-13	Takeda Receives a Decision by the President of National Tax Tribunal Relating to the Correction Notice on Transfer Pricing
27-Mar-13	Takeda Submits a New Drug Application for the Fixed-Dose Combination of Takepron and Low-Dose Aspirin in Japan
27-Mar-13	Takeda Submits New Drug Applications in Japan for Cell Culture-Based Pandemic Influenza Vaccines with its Hikari Plant